Price (delayed)
$30.8
Market cap
$3.33B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.39
Enterprise value
$3.82B
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating
There are no recent dividends present for NVCR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.